title: Weight reduction effects of a black soy peptide supplement in overweight and obese subjects: double blind, randomized, controlled study.
abstract: The present study determined the effect of black soy peptide supplementation on body weight and body fat in overweight/obese subjects. In a double-blind controlled trial, participants (n = 80) were randomized to either soy peptide supplementation (the test group) or to a placebo (the placebo group). Sixty-four people completed the study, and anthropometric parameters, serum inflammatory markers, and leptin and lipid profiles were measured. After 6 weeks, the test group (n = 35) had significant reductions in body weight (p = 0.003) and body mass index (BMI) (p = 0.004), body fat mass (p = 0.038). After 12 weeks, they also had significant reductions in body weight (p < 0.001), BMI (p < 0.001), body fat percentage (p = 0.002), and body fat mass (p = 0.001). However, these significances were not observed in the placebo group (n = 29). In addition, net changes in body weight and body fat mass in the test group were significantly bigger than those in the placebo group after 12 weeks. Leptin levels were significantly reduced in the test groups (p = 0.047), but were not observed in the placebo group (p = 0.323). Interestingly, the subjects with weight reductions ≥1kg in the test group had greater reductions in circulating leptin levels (p = 0.002). Additionally, fasting insulin levels were significantly reduced in the test groups. The conclusion is that black soy peptide supplementation may be beneficial for body weight control in overweight/obese subjects.
authors: Yonsei University Research Institute of Science for Aging, Yonsei University, Seoul, Korea.
authors: Jung Hyun
authors: JH
authors: Kwak
authors: Chang-Won
authors: CW
authors: Ahn
authors: Soo-Hyun
authors: SH
authors: Park
authors: Sung-Ug
authors: SU
authors: Jung
authors: Byung-Jung
authors: BJ
authors: Min
authors: Oh Yoen
authors: OY
authors: Kim
authors: Jong Ho
authors: JH
authors: Lee
mesh_terms: D000273:Adipose Tissue / Q000187:drug effects / Q000378:metabolism; D000328:Adult; D000368:Aged; D016632:Apolipoprotein A-I / Q000097:blood; D001055:Apolipoproteins B / Q000097:blood; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000032:analysis; D001823:Body Composition / Q000187:drug effects; D015992:Body Mass Index; D002097:C-Reactive Protein / Q000378:metabolism; D019587:Dietary Supplements; D004311:Double-Blind Method; D005215:Fasting; D005260:Female; D006801:Humans; D007328:Insulin / Q000097:blood; D053583:Interleukin-1beta / Q000097:blood; D020738:Leptin / Q000097:blood; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000188:drug therapy*; D050177:Overweight / Q000188:drug therapy*; D030262:Soybean Proteins / Q000008:administration & dosage*; D013025:Glycine max / Q000737:chemistry*; D014409:Tumor Necrosis Factor-alpha / Q000097:blood; D015431:Weight Loss / Q000187:drug effects*
chemical_list: D016632:Apolipoprotein A-I; D001055:Apolipoproteins B; D015415:Biomarkers; D001786:Blood Glucose; D007328:Insulin; D053583:Interleukin-1beta; D020738:Leptin; D008055:Lipids; D030262:Soybean Proteins; D014409:Tumor Necrosis Factor-alpha; D002097:C-Reactive Protein